Newsight Tech Angels has invested in Aptadel Therapeutics, a Barcelona-based biotechnology company developing an innovative aptamer–drug conjugate (ApDC) platform for the treatment of childhood and rare cancers.
This marks NTA’s first investment in a Spanish company. Through the investment, NTA will support Aptadel’s clinical development and expansion into Japan and the broader Asian market, helping bring innovative therapeutic technologies to patients in need.